12:00 AM
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CNV2197944: Phase II started

Convergence Pharmaceuticals Ltd. (Cambridge, U.K.) began a double-blind, placebo-controlled Phase II trial to evaluate repeat doses of oral CNV2197944. As...

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >